Lawrence Ira D 4
4 · SCICLONE PHARMACEUTICALS INC · Filed May 24, 2011
Insider Transaction Report
Form 4
Lawrence Ira D
Director
Transactions
- Exercise/Conversion
Common Stock
2011-05-23$2.23/sh+30,000$66,900→ 30,000 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2011-05-23$5.77/sh−30,000$173,100→ 0 totalExercise: $2.23Exp: 2019-06-09→ Common Stock (30,000 underlying) - Sale
Common Stock
2011-05-20$5.77/sh−30,000$173,187→ 0 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2011-05-20$5.77/sh−30,000$173,187→ 0 totalExercise: $1.75Exp: 2018-06-10→ Common Stock (30,000 underlying) - Exercise/Conversion
Common Stock
2011-05-20$1.75/sh+30,000$52,500→ 30,000 total - Sale
Common Stock
2011-05-23$5.77/sh−30,000$173,100→ 0 total
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.76 to $5.7947.
- [F2]The price reported in Column 4 is a weighted average price. These share were sold in multiple transactions at prices ranging from $5.74 to$5.79
- [F3]Granted under the Issuer's 2004 Outside Directors Stock Option Plan.
- [F4]Each option shall vest and become exercisable at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant except that, in the event of a change in control, any unexercisable or unvested portions of outstanding options shall be immediately exercisable and vested in full as of the date ten (10) days prior to the change in control, regardless of whether the option is assumed or substituted for by the acquirer.